HIGHLIGHTS
- who: Aaron Yarlas from the (UNIVERSITY) have published the Article: The impact of inotersen on neuropathy impairment score in patients with hereditary transthyretin amyloidosis with polyneuropathy, in the Journal: (JOURNAL)
- what: Based on the evidential gaps described here, this study had three objectives. The aim was to compare, within patient subgroups defined by key clinical characteristics, mean changes in NIS and NIS-LL total and subscale scores after 65 weeks between patients with ATTRv-PN receiving inotersen or placebo in the NEURO-TTR trial. Due to very few patients in the study showing signs of . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.